06:36 AM EDT, 09/30/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said on Friday that long-term data from the Phase 3 study of its experimental therapy, Carvyktif, showed statistically significant and clinically meaningful improvement in overall survival in certain patients with relapsed or lenalidomide-refractory multiple myeloma.

The company said the three-year follow-up data from the study also showed a single infusion of Carvykti reduced the risk of death in patients by 45% compared to standard therapies.

Price: 162.03, Change: +0.63, Percent Change: +0.39